-
Sotorasib, sold
under the
brand names Lumakras and Lumykras, is an anti-cancer
medication used to
treat non-small-cell lung cancer. It
targets a specific...
-
designation to
sotorasib for
advanced or
metastatic non-small cell lung
cancer patients with KRAS G12C mutation. In May 2021,
sotorasib received accelerated...
- the
respiratory system if inhaled. ACBI3
Adagrasib Olomorasib RMC-9805
Sotorasib "MRTX 1133". AdisInsight.
Springer Nature Switzerland AG.
Zeissig MN,...
-
adenocarcinomas (PDACs) have a KRAS mutation.
There is one
approved drug,
sotorasib, that
targets the KRAS G12C mutation, but only ~1% of
PDACs have this...
- 80%
disease control rate (n = 32). ACBI3
Adagrasib MRTX1133
Olomorasib Sotorasib "RMC-9805". AdisInsight.
Springer Nature Switzerland AG. "KRAS G12D inhibitor...
- and
advanced solid tumors. ACBI3
Adagrasib MRTX1133
Olomorasib RMC-9805
Sotorasib Ros J,
Vaghi C,
Baraibar I,
Saoudi González N, Rodríguez-Castells M, García...
-
finding effective inhibitors for the Kras-G12C mutation. For instance,
sotorasib (Lumakras)
became the
first FDA-approved
targeted therapy for the treatment...
- L01XX67
Tagraxofusp L01XX69
Lurbinectedin L01XX72
Tazemetostat L01XX73
Sotorasib L01XX74
Belzutifan L01XX75
Tebentafusp L01XX77
Adagrasib L01XX78 Navitoclax...
- and
advanced solid tumors. ACBI3
Adagrasib Divarasib MRTX1133 RMC-9805
Sotorasib Peng SB, Si C,
Zhang Y, Van Horn RD, Lin X, Gong X, et al. (July 2021)...
- non-small cell lung
cancer who may
benefit from
treatment with
Lumakras (
sotorasib)" in late 2021. The
agency granted regulatory approval of the test in...
